A Stanford bioethicist compares the possible hazards of stem cells with the challenges gene therapy faced a decade ago.
I don’t feel I have enough experience with university IRBs to judge whether stem cells need more regulatory oversight. Before reading this, I didn’t realize the FDA had placed a hold on the first clinical trial using a ES-cell-derived product. I aim to pay closer attention to this issue.
The clinical trial in question would deal with spinal cord injury. It appears that experts in cardiac muscle repair also disagree over whether enough is known about how stem cells work in that arena.